title: A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants.
abstract: There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. MegaFasL selectively kills hematological cancer cells from lymphomas and leukemias and prevents tumor development at concentrations that do not reduce the functional capacity of human hematopoietic stem/progenitor cells both in in vitro and in in vivo transplantation models. These findings highlight the potential use of MegaFasL as an ex-vivo purging agent in ASCT.
authors: A
authors: A
authors: Nahimana
authors: D
authors: D
authors: Aubry
authors: L
authors: L
authors: Lagopoulos
authors: P
authors: P
authors: Greaney
authors: A
authors: A
authors: Attinger
authors: S
authors: S
authors: Demotz
authors: K M
authors: KM
authors: Dawson
authors: M
authors: M
authors: Schapira
authors: J
authors: J
authors: Tschopp
authors: M
authors: M
authors: Dupuis
authors: M A
authors: MA
authors: Duchosal